PLD1 is a key player in cancer stemness and chemoresistance: Therapeutic targeting of cross-talk between the PI3K/Akt and Wnt/β-catenin pathways

참고문헌 (97)

1. Ebrahimi, N., "Cancer stem cells in colorectal cancer : signaling pathways involved in stemness and therapy resistance", Crit. Rev. Oncol. Hematol, 182, pp.103920~ (2023)
2. Telang, N., "Drug-resistant stem cells : novel approach for colon cancer therapy", Int. J. Mol. Sci, 23, pp.2519~ (2022)
3. Nasrolahi, A., "Signaling pathways governing glioma cancer stem cells behavior", Cell Signal, 101, pp.110493~ (2023)
4. Tomar, M. S., "Elucidating the mechan isms of Temozolomide resistance in gliomas and the strategies to overcome the resistance", Biochim Biophys. Acta Rev. Cancer, 1876, pp.188616~ (2021)
5. Boyd, N. H., "Glioma stem cells and their roles within the hypoxic tumor microenvironment", Theranostics, 11, pp.665~683 (2021)
6. Schwitalla, S., "Intestinal tumorigenesis initiated by dedifferentiation and acquisition of stem-cell-like properties", Cell, 152, pp.25~38 (2013)
7. Saygin, C., "Targeting cancer stemness in the clinic : from hype to hope", Cell Stem Cell, 24, pp.25~40 (2019)
8. Aramini, B., "Dissecting tumor growth: the role of cancer stem cells in drug resistance and recurrence", Cancers(Basel), 14, pp.976~ (2022)
9. Yuan, S., "Role of Wnt", β-catenin signaling in the chemoresistance modulation of colorectal cancer, 2020, pp.2020, 9390878~
10. Bian, J., "Transcriptional regulation of Wnt", β-catenin pathway in colorectal cancer, 2020, pp.9, 2125~
11. Kim, Y., "Wnt", β-catenin pathway is a key signaling pathway to trastuzumab resistance in gastric cancer cells, 2023, pp.23, 922~
12. McCord, M., "Targeting WNT sig naling for multifaceted glioblastoma therapy", Front Cell Neurosci, 11, pp.318~ (2017)
13. Sareddy, G. R., "PELP1 promotes glioblastoma progression by enhancing Wnt", β-catenin signaling, 2019, pp.1, vdz042~
14. Guan, R., "Glioblastoma stem cells and Wnt signaling pathway : molecular mechanisms and therapeutic targets", Chin. Neurosurg. J, 6, pp.25~ (2020)
15. Kang, D. W., "Targeting phospholipase D1 attenuates intestinal tumorigenesis by controlling β-catenin signaling in cancer-initiating cells", J. Exp. Med, 212, pp.1219~1237 (2015)
16. Kang, D. W., "Phospholipase D1 inhibition linked to upregulation of ICAT blocks colorectal cancer growth hyperactivated by Wnt", β-catenin and PI3K, Clin. Cancer Res, pp.2017, 23[DOI]
17. Kang, D. W., "Phospholipase D1inhibition sensitizes glioblastoma to temozolomide and suppresses its tumor igenicity", J. Pathol, 252, pp.304~316 (2020)
18. Kang, D. W., "Phospholipase D1 acts through Akt", TopBP1 and RB1 to regulate the E2F1-dependent apoptotic program in cancer cells, 2017, pp.77, 142~152
19. Bruntz, R. C., "Phospholipase D signaling pathways and phosphatidic acid as therapeutic targets in cancer", Pharm. Rev, 66, pp.1033~1079 (2014)
20. Huang, P., "The potential for phospholipase D as a new ther apeutic target", Expert Opin. Ther. Targets, 11, pp.707~716 (2007)
21. Gomez-Cambronero, J., "Phospholipase D in cell signaling : from a myriad of cell functions to cancer growth and metastasis", J. Biol. Chem, 289, pp.22557~22566 (2014)
22. Kang, D. W., "Functional regulation of phospholipase D expression in cancer and inflammation", J. Biol. Chem, 289, pp.22575~22582 (2014)
23. McDermott, M. I., "Mammalian phospholipase D : function, and therapeutics", Prog. Lipid Res, 78, pp.101018~ (2020)
24. Yao, Y., "Phospholipase D as a key modulator of cancer progression", Biol. Rev. Camb. Philos. Soc, 95, pp.911~935 (2020)
25. Brown, H. A., "Targeting phospholipase D in cancer, infection and neurodegenerative disorders", Nat. Rev. Drug Discov, 16, pp.351~367 (2017)
26. Selvy, P. E., "Phospholipase D : enzymology, functionality, and chemical modulation", Chem. Rev, 111, pp.6064~6119 (2011)
27. Kang, D. W., "Phospholipase D meets Wnt signaling : a new target for cancer therapy", Cancer Res, 71, pp.293~297 (2011)
28. Frias, M. A., "Regulation of mTOR by phosphatidic acid", Trends Endocrinol. Metab, 34, pp.170~180 (2023)
29. Kang, D. W., "Phospholipase D1 drives a positive feedback loop to reinforce the Wnt", beta-catenin, Cancer Res, pp.2010, 70[DOI]
30. Kang, D. W., "Positive feedback regulation between phospholipase D and Wnt signaling promotes Wnt-driven anchorage-independent growth of colorectal cancer cells", PLoS One, 5, pp.e12109~ (2010)
31. Hwang, W. C., "Inhibition of phospholipase D1 induces immunogenic cell death and potentiates cancer immunotherapy in colorectal cancer", Exp. Mol. Med, 54, pp.1563~1576 (2022)
32. Hagerstrand, D., "Systematic interrogation of 3q26 identifies TLOC1 and SKIL as cancer drivers", Cancer Discov, 3, pp.1044~1057 (2013)
33. Kang, D. W., "Phorbol ester up-regulates phospholipase D1 but not phos pholipase D2 expression through a PKC", Ras, NFkappaB-dependent pathway and enhances matrix metalloproteinase-9 secretion in colon cancer cells, pp.J. Biol. Chem, 2008[DOI]
34. Hatakeyama, M., "Linking epithelial polarity and carcinogenesis by multitasking Helicobacter pylori virulence factor CagA", Oncogene, 27, pp.7047~7054 (2008)
35. Kang, D. W., "Rebamipide abolishes Helicobacter pylori CagA-induced phospholipase D1 expression via inhibition of NFκB and suppresses invasion of gastric cancer cells", Oncogene, 32, pp.3531~3542 (2013)
36. Gao, S., "Mutated ras induced PLD1 gene expression through increased Sp1transcription factor", Nagoya J. Med Sci, 71, pp.127~136 (2009)
37. Buchanan, F. G., "Requirement of phospholipase D1 activity in H-RasV12induced transformation", Proc. Natl. Acad. Sci. USA, 102, pp.1638~1642 (2005)
38. Kikuchi, R., "Ewing’s sarcoma fusion protein, EWS", Fli-1 and Fli-1 protein induce PLD2 but not PLD1 gene expression by binding to an ETS domain of 5′promoter, 2007, pp.26, 1802~1810
39. Janardhan, S., "Choline kinase : an important target for cancer", Curr. Med Chem, 13, pp.1169~1186 (2006)
40. Brailoiu, E., "Choline is an intracellular messenger linking extracellular stimuli to IP3-evoked Ca2+ signals through sigma-1 receptors", Cell Rep, 26, pp.330~337 (2019)
41. Chittim, C. L., "Gut bacterial phospholipase Ds support disease-associated metabolism by generating choline", Nat. Microbiol, 4, pp.155~163 (2019)
42. Krueger, S. K., "Mammalian flavin-containing monooxygenases : structure", function, genetic polymorphisms and role in drug metabolism, 2005, pp.106, 357~387
43. Zhao, C., "Phospholipase D2generated phosphatidic acid couples EGFR stimulation to Ras activation by Sos", Nat. Cell Biol, 9, pp.706~712 (2007)
44. Zhang, Y., "Phosphatidic acid signaling regulation of Ras superfamily of small guanosine triphosphatases", Biochim. Biophys. Acta, 1791, pp.850~855 (2009)
45. Foster, D. A., "Phosphatidic acid signaling to mTOR : signals for the survival of human cancer cells", Biochim. Biophys. Acta, 1791, pp.949~955 (2009)
46. Foster, D. A., "Phospholipase D and the maintenance of phosphatidic acid levels for regulation of mammalian target of rapamycin(mTOR)", J. Biol. Chem, 289, pp.22583~22588 (2014)
47. Fang, Y., "Phosphatidic acid mediated mitogenic activation of mTOR signaling", Science, 294, pp.1942~1945 (2001)
48. Chen, Y., "Phospholipase D confers rapamycin resistance in human breast cancer cells", Oncogene, 22, pp.3937~3942 (2003)
49. Kim, J., "Phospholipase D prevents etoposide-induced apoptosis by inhibiting the expression of early growth response-1 and phosphatase and tensin homo logue deleted on chromosome 10", Cancer Res, 66, pp.784~793 (2006)
50. Jang, Y. H., "Differential regulation of apoptosis by caspase-mediated clea vage of phospholipase D isozymes", Cell Signal, 20, pp.2198~2207 (2008)
51. Kim, S. Y., "Phospholipase D isozymes mediate epigallocatechin gallate induced cyclooxygenase-2 expression in astrocyte cells", J. Biol. Chem, 279, pp.38125~38133 (2004)
52. Jang, J. H., "Understanding of the roles of phospholipase D and phosphatidic acid through their binding partners", Prog. Lipid Res, 51, pp.71~81 (2012)
53. Park, M. H., "Phospholipase D2 promotes degradation of hypoxia-inducible factor-1α independent of lipase activity", Exp. Mol. Med, 47, pp.e196~ (2015)
54. Park, M. H., "Phospholipase D1 protein coordinates dynamic assembly of HIF-1α-PHD-VHL to regulate HIF-1α stability", Oncotarget, 5, pp.11857~11872 (2014)
55. Kim, M. K., "Pleckstrin homology domain of phospho lipase D2 is a negative regulator of focal adhesion kinase", BMB Rep, 54, pp.112~117 (2021)
56. Zhang, K., "ICAT inhibits glioblastoma cell proliferation by suppressing Wnt", β-catenin activity, 2015, pp.357, 404~411
57. MacDonald, B. T., "Wnt", beta-catenin signaling: components, mechanisms, and diseases, 2009, pp.17, 9~26
58. Cavallo, R. A., "Drosophila Tcf and Groucho interact to repress Wingless signalling activity", Nature, 395, pp.604~608 (1998)
59. Roose, J., "The Xenopus Wnt effector XTcf-3 interacts with Groucho-related transcriptional repressors", Nature, 395, pp.608~612 (1998)
60. Tago, K., "Inhibition of Wnt signaling by ICAT, a novel beta-catenin interacting protein", Genes Dev, 14, pp.1741~1749 (2000)
61. Gottardi, C. J., "Role for ICAT in beta-catenin-dependent nuclear signaling and cadherin functions", Am. J. Physiol. Cell Physiol, 286, pp.C747~C756 (2004)
62. Sekiya, T., "Overexpression of Icat induces G(2)arrest and cell death in tumor cell mutants for adenomatous polyposis coli, beta-catenin, or Axin", Cancer Res, 62, pp.3322~3326 (2002)
63. Morris, E. J., "E2F1 represses beta-catenin transcription and is antagonized by both pRB and CDK8", Nature, 455, pp.552~556 (2008)
64. Bramis, J., "E2F-1 transcription factor immunoexpression is inversely asso ciated with tumor growth in colon adenocarcinomas", Anticancer Res, 24, pp.3041~3047 (2004)
65. Liu, K., "Regulation of TopBP1 oligo merization by Akt", PKB for cell survival, 2006, pp.25, 4795~4807
66. Arqués, O., "Tankyrase inhibition blocks Wnt", β-catenin pathway and reverts resistance to PI3K and AKT inhibitors in the treatment of colorectal cancer, 2016, pp.22, 644~656
67. Tenbaum, S. P., "β-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer", Nat. Med, 18, pp.892~901 (2012)
68. DeRose, Y. S., "Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes", Nat. Med, 17, pp.1514~1520 (2011)
69. Trimarchi, J. M., "Sibling rivalry in the E2F family", Nat. Rev. Mol. Cell Biol, 3, pp.11~20 (2002)
70. Lai, P. S., "Overexpression of RB1 transcript is significantly correlated with 13q14allelic imbalance in colorectal carcinomas", Int. J. Cancer, 119, pp.1061~1066 (2006)
71. Firestein, R., "CDK8 is a colorectal cancer oncogene that regulates beta catenin activity", Nature, 455, pp.547~551 (2008)
72. Park, M. H., "Overexpression of phospholipase D enhances matrix metalloproteinase-2 expression and glioma cell invasion via protein kinase C and protein kinase A", NF-kappaB, Carcinogenesis, pp.2009, 30[DOI]
73. Kang, D. W., "Phospholipase D1 is upregulated by vorinostat and confers resistance to vorinostat in glioblastoma", J. Cell Physiol, 236, pp.549~560 (2021)
74. Bruntz, R. C., "Phospholipase D2mediates survival signaling through direct regulation of Akt in glioblastoma cells", J. Biol. Chem, 289, pp.600~616 (2014)
75. Mathews, T. P., "Human phospholipase D activity transiently regulates pyr imidine biosynthesis in malignant gliomas", ACS Chem. Biol, 10, pp.1258~1268 (2015)
76. Liu, C., "Wnt", beta-Catenin pathway in human glioma : expression pattern and clinical, Clin. Exp. Med, pp.2011, 11[DOI]
77. Gratas, C., "BakandMcl-1areessential for Temozolomide induced cell death in human glioma", Oncotarget, 5, pp.2428~2435 (2014)
78. Yi, G. Z., "Akt and β-catenin contribute to TMZ resistance and EMT of MGMT negative malignant glioma cell line", J. Neurol. Sci, 367, pp.101~106 (2016)
79. Zhao, Y., "The role of canonical Wnt signaling in regulating radioresistance", Cell Physiol. Biochem, 48, pp.419~432 (2018)
80. Kang, D. W., "MicroRNA-320a and microRNA-4496 attenuate Helicobacter pylori cytotoxin-associated gene A(CagA)-induced cancer-initiating potential and chemoresistance by targeting β-catenin and ATP-binding cassette, subfamily G, member 2", J. Pathol, 241, pp.614~625 (2017)
81. Kang, D. W., "Rebamipide attenuates Helicobacter pylori CagA-induced self-renewal capacity via modula tion of β-catenin signaling axis in gastric cancer-initiating cells", Biochem Pharm, 113, pp.36~44 (2016)
82. Esteller, M., "Epigenetics in cancer", N. Engl. J. Med, 358, pp.1148~1159 (2008)
83. Monovich, L., "Optimization of halopemide for phospholipase D2 inhibition", Bioorg. Med Chem. Lett, 17, pp.2310~2311 (2007)
84. Loonen, A. J., "Effects of halopemide on GABA receptor binding, uptake and release", Brain Res, 210, pp.485~492 (1981)
85. Scott, S. A., "Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness", Nat. Chem. Biol, 5, pp.108~117 (2009)
86. decan-8-yl)ethyl)benzamides:discovery of an isoform-selective small molecule phospholipase D2 inhibitor, "J. Med. Chem", 2010, 6706~6719
87. Lewis, J. A., "Design and synthesis of isoform-selective phospholipase D (PLD)inhibitors. Part I: impact of alternative halogenated privileged structures for PLD1 specificity", Bioorg. Med Chem. Lett, 19, pp.1916~1920 (2009)
88. Ghim, J., "Accumulating insights into the role of phospholipase D2 in human diseases", Adv. Biol. Regul, 61, pp.42~46 (2016)
89. decane Core: discovery of Ml298 and Ml299that decrease invasive migration in U87-MG glioblastoma cells, "J. Med. Chem", 2013, 2695~2699
90. Thielmann, I., "Redundant functions of phospholipases D1 and D2 in platelet α-granule release", J. Thromb. Haemost, 10, pp.2361~2372 (2012)
91. Jang, Y. H., "Phospholipase D-mediated autophagic reg ulation is a potential target for cancer therapy", Cell Death Differ, 21, pp.533~546 (2014)
92. Bowling, F. Z., "Crystal structure of human PLD1 provides insight into acti vation by PI(4, 5)P(2)and RhoA", Nat. Chem. Biol, 16, pp.400~407 (2020)
93. Metrick, C. M., "Human PLD structures enable drug design and character ization of isoenzyme selectivity", Nat. Chem. Biol, 16, pp.391~399 (2020)
94. Fucikova, J., "Detection of immunogenic cell death and its relevance for cancer therapy", Cell Death Dis, 11, pp.1013~ (2020)
95. Galluzzi, L., "Immunogenic cell death in cancer and infectious disease", Nat. Rev. Immunol, 17, pp.97~111 (2017)
96. Xiao, Q., "DKK2 imparts tumor immunity evasion through β-catenin-inde pendent suppression of cytotoxic immune-cell activation", Nat. Med, 24, pp.262~270 (2018)
97. Mu, C. Y., "High expression of PD-L1in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation", Med. Oncol, 28, pp.682~688 (2011)

관련 논문AI추천